This is a working overview of 生长激素释放激素, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-20. Anything still debated is marked as such rather than presented as settled.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
== Clinical significance == 11-Deoxycortisol in mammals has limited glucocorticoid activity, but it is the direct precursor of the major mammalian glucocorticoid, cortisol. As a result, the level of 11-deoxycortisol is measured to diagnose impaired cortisol synthesis, to find out the enzyme deficiency that causes impairment along the pathway to cortisol, and to differentiate adrenal disorders. In 11β-hydroxylase deficiency, 11-deoxycortisol and 11-deoxycorticosterone levels increase, and excess of 11-deoxycorticosterone leads to mineralocorticoid-based hypertension (as opposed to 21-hydroxylase deficiency, in which patients have low blood pressure from a lack of mineralocorticoids). Low levels of cortisol can affect blood pressure by causing a decrease in sodium retention and volume expansion. This effect occurs because cortisol regulates the balance of water and electrolytes in the body. When cortisol levels are low, there is less sodium reabsorption by the kidneys, leading to increased excretion of sodium through urine. This ultimately reduces blood volume and lowers blood pressure. On the other hand, high levels of cortisol can also affect blood pressure by causing an increase in sodium retention and volume expansion. Cortisol-induced hypertension is accompanied by significant sodium retention, leading to an increase in extracellular fluid volume and exchangeable sodium. This expansion results in an increase in blood volume and subsequently increases blood pressure.
=== Phase 3 === Benzoyl peroxide/tretinoin (IDP-120) – combination of benzoyl peroxide (undefined mechanism of action) and tretinoin (retinoid) Berdazimer sodium (SB-204; MAP3-NONOate; NVN1000) – nitric oxide releasing agent Denifanstat (ASC–40; TVB-2640) – fatty acid synthetase complex inhibitor GED 0507-34-Levo (GED-0507; GED-0507-34; N-acetyl-GED-0507-34; NAC-GED-0507) – peroxisome proliferator-activated receptor gamma (PPARγ) modulator
o-Coumaric acid is a hydroxycinnamic acid, an organic compound that is a hydroxy derivative of cinnamic acid. There are three isomers of coumaric acids — o-coumaric acid, m-coumaric acid, and p-coumaric acid — that differ by the position of the hydroxy substitution of the phenyl group.
== Responsibilities == The Treuhand was responsible for more than just the 8,500 state-owned enterprises. It also took over around 2.4 million hectares of agricultural land and forests, the property of the former Stasi, large parts of the property of the former National People's Army, large-scale public housing property, and the property of the state pharmacy network. On 3 October 1990, the day of reunification, it took over the property of the SED, as well as the other political parties and the mass organisations of the National Front.
Sources: en.wikipedia.org
Monster Energy is the primary sponsor for Yamaha Motor Racing in MotoGP since 2019 and also sponsors riders such as Valentino Rossi, Franco Morbidelli, and Francesco Bagnaia. The firm has also been the title sponsor of the Catalan motorcycle Grand Prix since 2014, and the British motorcycle Grand Prix since 2021. The brand has been the main sponsor of the Speedway Grand Prix and Speedway World Cup since 2012, and also supports several riders. Monster has sponsored motocross riders such as Jeremy McGrath, Chad Reed, Ryan Villopoto, Nate Adams, Taka Higashino and Ricky Carmichael. The brand sponsors the Kawasaki, and Yamaha motocross factory teams. In 2016, the firm aided the return of factory Yamaha to the United States as the title sponsor of the team, officially named Monster Energy/360fly/Chaparral/Yamaha Factory Racing. During this time, Monster Energy served as a title sponsor for the Star Racing Yamaha team, which also took over the 450 program from Factory Yamaha in 2021. They have gone on to win the 2021 AMA Pro Motocross Championship with Dylan Ferrandis, and the 2022 AMA Supercross and AMA Pro Motocross Championships with Eli Tomac. The brand is also the main sponsor of the Honda and Hero factory teams in the FIM Cross-Country Rallies World Championship and later the World Rally-Raid Championship since 2016 and 2023 respectively.
=== Republic of Egypt (from 1953) === King Hussein of Jordan, 1955 Marshal Josip Broz Tito, President of the Federal People's Republic of Yugoslavia, 1956 Prof. Amintore Fanfani, Prime Minister and ad-interim Minister of Foreign Affairs of the Republic of Italy, 1959 Yuri Gagarin, Soviet cosmonaut, 1961 Taha Hussein, Egyptian writer, 1965 Umm kulthum, Egyptian singer and actress, 1965 Mohammed Abdel Wahab, Egyptian singer and composer, 1965 President Jimmy Carter, President of the United States, 1979 Emperor Akihito of Japan Emperor Amha Selassie of Ethiopia Mohammed Burhanuddin, 52nd Da'i al-Mutlaq of the Dawoodi Bohra, 1978 King Bhumibol Adulyadej of Thailand Mohamed ElBaradei, former director general of the International Atomic Energy Agency (IAEA) Queen Elizabeth II, 1975 Birendra Bir Bikram shah Dev, King of Nepal, 1974 Mohammad Reza Pahlavi, Shah of Iran, 1975 Hassaballah El Kafrawy, Egyptian former Minister of Housing Pengiran Anak Haji Mohamed Yusof, prince consort and cheteria of Brunei, 1984 Naguib Mahfouz, Egyptian writer, 1988 King Fahd bin Abdulaziz Al Saud of Saudi Arabia, 1989 Pierre Gemayel, founder of the Lebanese Phalange Emperor Haile Selassie of Ethiopia King Hamad bin Isa Al Khalifa of Bahrain, 2016 King Idris of Libya (Grand Cordon) Ekmeleddin İhsanoğlu, Turkish academic, diplomat and former Secretary-General of the Organisation of Islamic Cooperation (OIC) Émile Lahoud, President of Lebanon, 2000 Makarios III, former president of Cyprus Nelson Mandela, President of South Africa Adly Mansour, former Chief Justice of the Supreme Constitutional Court and former acting President of Egypt King Mohammed VI of Morocco Muhammad Naguib, First President of Egypt Nursultan Nazarbayev, President of Kazakhstan Antonín Novotný, President of Czechoslovakia Sultan Qaboos bin Said al Said of Oman, 1976 Ziaur Rahman, President of Bangladesh Heinrich Rau, East German politician (Grand Cordon), 1961 King Saud bin Abdulaziz Al Saud of Saudi Arabia, 1954 King Norodom Sihanouk of Cambodia William E. Simon, U.S. Secretary of the Treasury Suharto, President of Indonesia Field Marshal Mohamed Hussein Tantawi, former chairman of the Supreme Council of the Armed Forces of Egypt, 2012 Walter Ulbricht, President of East Germany, 1965 George Vasiliou, former president of Cyprus Sir Magdi Habib Yacoub, Egyptian professor of Cardiothoracic Surgery Professor Ahmed Zewail, Egyptian scientist Katerina Sakellaropoulou, President of Greece, 2020 Salva Kiir Mayardit, President of South Sudan, 2020 Haitham bin Tariq, Sultan of Oman, 2023 Narendra Modi, Prime Minister of India, 2023 Mufaddal Saifuddin, 53rd Da'i al-Mutlaq of the Dawoodi Bohras, 2023 Mishal Al-Ahmad Al-Jaber Al-Sabah, Emir of Kuwait, 2024 King Frederik X, King of Denmark, 2024 King Felipe VI, King of Spain, 2025 Donald Trump, President of the United States, 2025
=== Phrixotoxin-1 === Mice that are injected with phrixotoxin-1 can experience numerous, transient, adverse cardiac reactions, such as premature ventricular beats, ventricular tachycardia, and atrio-ventricular blocks. Neurological effects observed are motor impairment and convulsions. These effects are seen following both intravenous and intracisternal injection, making it likely that phrixotoxin-1 crosses the blood brain barrier (Diochot 1999).
A newly developed ELISA system utilises genetically modified citrullinated vimentin (MCV), a naturally occurring isoform of vimentin to optimize the performance of the test. Noteworthy are the findings of a recently published study that highly valuates anti-MCV test systems for diagnosing rheumatoid arthritis in anti-CCP-negative patients. However, data from all around the world vary substantially. Anti-CCP is also very useful in the early diagnosis of rheumatoid arthritis in high-risk groups, such as relatives of RA patients, although Silman and co-workers found that the concordance rate of developing RA was 15.4% among identical (monozygotic) twins and was 3.6% among fraternal (dizygotic) twins. Given that ACPA are more specific than rheumatoid factor, they are used to distinguish various causes of arthritis. Novel assays may be useful for monitoring disease activity and effects of RA therapy. The reference ranges for blood tests of anti–citrullinated protein antibodies are:
The vagina is attached to the pelvic walls by endopelvic fascia. The peritoneum is the external layer of skin that covers the fascia. This tissue provides additional support to the pelvic floor. The endopelvic fascia is one continuous sheet of tissue and varies in thickness. It permits some shifting of the pelvic structures. The fascia contains elastic collagen fibers in a 'mesh-like' structure. The fascia also contains fibroblasts, smooth muscle, and vascular vessels. The cardinal ligament supports the apex of the vagina and derives some of its strength from vascular tissue. The endopelvic fascia attaches to the lateral pelvic wall via the arcus tendineus.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。